Q&A: What to know about the new BA 2.86 COVID variant


The Centers for Disease Control and Prevention and the World Health Organization have dubbed the BA 2.86 variant of COVID-19 as a variant to watch.

So far, only 26 cases of “Pirola,” as the new variant is being called, have been identified: 10 in Denmark, four each in Sweden and the United States, three in South Africa, two in Portugal, and one each the United Kingdom, Israel, and Canada. BA 2.86 is a subvariant of Omicron, but according to reports from the CDC, the strain has many more mutations than the ones that came before it.

With so many facts still unknown about this new variant, this news organization asked experts what people need to be aware of as it continues to spread.

What is unique about the BA 2.86 variant?

“It is unique in that it has more than three mutations on the spike protein,” said Purvi S. Parikh, MD, an infectious disease expert at New York University’s Langone Health. The virus uses the spike proteins to enter our cells.

This “may mean it will be more transmissible, cause more severe disease, and/or our vaccines and treatments may not work as well, as compared to other variants,” she said.

What do we need to watch with BA 2.86 going forward?

“We don’t know if this variant will be associated with a change in the disease severity. We currently see increased numbers of cases in general, even though we don’t yet see the BA.2.86 in our system,” said Heba Mostafa, PhD, director of the molecular virology laboratory at Johns Hopkins Hospital in Baltimore.

“It is important to monitor BA.2.86 (and other variants) and understand how its evolution impacts the number of cases and disease outcomes,” she said. “We should all be aware of the current increase in cases, though, and try to get tested and be treated as soon as possible, as antivirals should be effective against the circulating variants.”

What should doctors know?

Dr. Parikh said doctors should generally expect more COVID cases in their clinics and make sure to screen patients even if their symptoms are mild.

“We have tools that can be used – antivirals like Paxlovid are still efficacious with current dominant strains such as EG.5,” she said. “And encourage your patients to get their boosters, mask, wash hands, and social distance.”

How well can our vaccines fight BA 2.86?

“Vaccine coverage for the BA.2.86 is an area of uncertainty right now,” said Dr. Mostafa.

In its report, the CDC said scientists are still figuring out how well the updated COVID vaccine works. It’s expected to be available in the fall, and for now, they believe the new shot will still make infections less severe, new variants and all.

Prior vaccinations and infections have created antibodies in many people, and that will likely provide some protection, Dr. Mostafa said. “When we experienced the Omicron wave in December 2021, even though the variant was distant from what circulated before its emergence and was associated with a very large increase in the number of cases, vaccinations were still protective against severe disease.”


Recommended Reading

Inflammation and immunity troubles top long-COVID suspect list
MDedge Endocrinology
Cardiac issues twice as likely with COVID plus high troponin
MDedge Endocrinology
COVID-19 shot appears to reduce diabetes risk, even after Omicron
MDedge Endocrinology
‘Breakthrough’ study: Diabetes drug helps prevent long COVID
MDedge Endocrinology
FREEDOM COVID: Full-dose anticoagulation cut mortality but missed primary endpoint
MDedge Endocrinology
Factors linked with increased VTE risk in COVID outpatients
MDedge Endocrinology
COVID can mimic prostate cancer symptoms
MDedge Endocrinology
Severe COVID-19 linked to new diabetes diagnoses
MDedge Endocrinology
Researchers seek to understand post-COVID autoimmune disease risk
MDedge Endocrinology
Review supports continued mask-wearing in health care visits
MDedge Endocrinology